



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST:36AAACC8372L1ZB

14/02/2019

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and all other applicable provisions and with reference to our letter dated 5th February, 2019, this is to inform you that the meeting of the Board of Directors of the company was held today ie; 14th February, 2019 at 4.00 P.M and concluded at 4.45 P.M., wherein the Board of directors of the company approved the Un-Audited Financial Results (Stand Alone and Consolidated) for the quarter and Nine Months Ended 31st December, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- 1) Statement of UnAudited Financial Results (Standalone and Consolidated) for the quarter and Nine Months Ended 31st December, 2018.
- 2) Auditors Report on Financial Results (Standalone and Consolidated).

We kindly request you to take the same on record and oblige.

Your Sincerely,
For **COMBAT DRUGS LIMITED**


SUSHANT MOHAN LAL
(DIRECTOR)



COMBAT DRUGS LIMITED

(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94, Sagar society, Banjara hills, Road No.2, Hyderabad- 34, Telangana, India

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Consolidated Financial Results For the Quarter and Nine Months Ended 31st December, 2018

All amounts in Lakhs, unless otherwise stated

Particulars	Quarter ended		Nine months ended	Year Ended
	31.12.2018	30.09.2018	31.12.2018	31.03.2018
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	64.34	133.32	683.92	50.42
II. Other income	-	0.62	0.31	62.58
III.Total revenue (I + II)	64.03	133.94	684.23	113.00
IV. Expenses				
Cost of materials consumed	-	120.00	600.32	43.42
Changes in inventories of finished goods and stock in trade	0.92	(12.58)	(21.41)	(2.70)
Depreciation and Amortization expense	0.03	-	0.03	-
Employee benefits expense	27.87	4.50	36.73	24.94
Other expenses	22.70	12.91	39.12	29.10
Total expenses	51.52	124.82	654.77	94.76
V. Profit/(Loss) before tax (III - IV)	12.51	9.12	29.46	18.24
VI. Tax expense:	-	-	-	-
(1) Current tax	-	-	-	-
(2) Deferred tax	-	-	-	-
VII. Profit/(Loss) for the period (V-VI)	12.51	9.12	29.46	18.24
VIII. Other comprehensive income				
Items that will be reclassified to statement of profit or loss:				
i) Exchange differences in translating the financial statements of a foreign subsidiary	0.55	(0.05)	0.50	-
IX. Total comprehensive income for the year	13.05	9.07	29.95	18.24
Total comprehensive income attributable to				
Owners of the parent	13.05	9.07	29.95	18.24
Non controlling Interests	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00
X. Earning per equity				
(1) Basic	0.16	0.11	0.37	0.23
(2) Diluted	0.16	0.11	0.37	0.23

Notes

- The above results for the quarter and nine months ended 31st December 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th February 2019
- According to the requirements of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, revenue for the Nine Months ended 31 December 2017 and year ended 31 March 2018 was reported inclusive of excise duty. Consequent to the introduction of Goods and Service Tax ("GST") with effect from 1 July 2017 which replaces excise duty and other input taxes, the revenue for the quarter and Nine Months ended 31 December 2018, 30 September 2018 and 31 December 2017 and is reported net of GST.
- The above results include results of wholly owned subsidiaries
-RA Labs Pte Ltd, Singapore and -ICP Solutions Private Limited, India
- The Group has only one reportable segment as per the requirements of Ind AS 108 "Operating Segments".
- The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
- The statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
- Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.
- Figures for the nine months ended 31st December, 2017 are not given since Consolidation of Financial Results are not published (option exercised to publish Standalone Results).



For and on Behalf of the Board

Sushant Mohan Lal
Director

Place: Hyderabad

Date : 14.02.2019

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL STATEMENTS**

To
The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Combat Drugs Limited ("Holding Company") and its wholly owned subsidiaries ICP Solutions Private Limited, India and RA Labs PTE Ltd, Singapore together referred to as "the Group"), for the quarter and nine months ended 31st December, 2018 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes financial results and other financial information of one subsidiary namely RA Labs PTE Ltd, Singapore whose interim financial results/information reflects total revenues of Rs. Nil lakhs and Rs. 0.68 lakhs for the quarter and nine months ended 31st December, 2018 respectively and net loss of Rs. 0.63 lakhs and Rs. 2.38 lakhs for the quarter and nine months ended 31st December, 2018 respectively. These interim financial results have been considered by the



Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the information submitted by the management. In our opinion and according to the information and explanations given to us by the Management, these financial results and other financial information are not material to the Group. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above and based on the consideration of the report of other auditor referred in paragraph above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Secunderabad
Date: 14.02.2019

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)



A.V. Sadasiva
Partner
M.No:018404

COMBAT DRUGS LIMITED
(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94, Sagar society, Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Standalone Financial Results For the Quarter and Nine Months Ended 31st December, 2018

All amounts in Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine months ended		Year Ended
	31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	36.47	133.30	15.06	655.37	18.65	101.63
II. Other income	-	0.62	28.13	0.31	51.04	11.37
III. Total revenue (I + II)	36.47	133.92	43.19	655.68	69.69	113.00
IV. Expenses						
Cost of materials consumed	-	120.00	12.93	600.32	13.73	43.42
Changes in inventories of finished goods and stock in trade	0.92	(12.58)	-	(21.41)	-	(2.70)
Depreciation and Amortisation expense	0.03	-	-	0.03	-	-
Employee benefits expense	3.94	4.50	9.78	12.79	22.95	24.94
Other expenses	19.63	10.65	9.52	33.86	17.49	29.10
Total expenses	24.52	122.56	32.23	625.58	54.17	94.76
V. Profit/(Loss) before tax (III - IV)	11.95	11.35	10.96	30.09	15.52	18.24
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	-	-	-	-	-	-
VII. Profit/(Loss) for the period (V-VI)	11.95	11.35	10.96	30.09	15.52	18.24
VIII. Other comprehensive income	-	-	-	-	-	-
IX. Total comprehensive income for the year	11.95	11.35	10.96	30.09	15.52	18.24
Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00	800.00	800.00
X. Earning per equity						
(1) Basic	0.15	0.14	0.14	0.38	0.19	0.23
(2) Diluted	0.15	0.14	0.14	0.38	0.19	0.23

Notes

- The above results for the quarter and nine months ended 31st December 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th February 2019.
- According to the requirements of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, revenue for the Nine Months ended 31 December 2017 and year ended 31 March 2018 was reported inclusive of excise duty. Consequent to the introduction of Goods and Service Tax ("GST") with effect from 1 July 2017 which replaces excise duty and other input taxes, the revenue for the quarter and Nine Months ended 31 December 2018, 30 September 2018 and 31 December 2017 is reported net of GST.
- The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- The statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
- Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on Behalf of the Board

Sushant Mohan Lal
Director

Place: Hyderabad
Date : 14.02.2019

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL STATEMENTS**

To
The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Combat Drugs Limited** ("the Company"), for the Quarter and Nine months ended 31st Dec,ember, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by the Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information* performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Secunderabad
Date: 14.02.2019

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)


A.V.Sadasiva
Partner
M.No.018404